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Live attenuated cold-adapted reassortant ( CR ) influenza virus vaccines were evaluated in 
institutionalized asthmatic children and severe psychomotor-retarded ( SPR) patients. 
Almost all the vaccinees were seropositive to the vaccine strains before immunization. 
Trivalent CR vaccine (containing A H1N1 (CR-125), A H3N2 (CR-149) and B 
( CRB-117)), bivalent CR vaccine (CR-125 and CR-149) and monovalent CRB-117 were 
inoculated to 19 asthmatic children and 36 and 16 SPR patients, respectively. Overall 
49, 22, and 11% of  vaccinees were infected by A H1N1, A H3N2 or B vaccine viruses, 
respectively, as indicated by significant haema991utination-inhibition (HI) antibody titre 
rises 4 weeks after inoculation. No severe adverse reactions associated with CR vaccination 
were observed in the handicapped patients. A nosocomial outbreak o f  influenza A H1N1 
occurred in the ward with asthmatic children, but none o f  the 19 CR-trivalent vaccinees 
became infected. However, five o f  20 non-vaccinees in the same ward, and ten o f  30 
vaccinees in another ward that received inactivated split vaccine became infected. The CR 
vaccines demonstrated significant protective effects against natural exposure to the A 
H1N1 virus, and were well tolerated and safe when given to patients with bronchial asthma 
and severe psychomotor retardation. 
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At present, it is recommended in Japan that the influenza 
split virus vaccine be given annually to school children. 
However, the effect of current vaccination programmes 
on morbidity is insignificant, and that on mortality 
marginal. Also, the antibody responses to inactivated 
vaccine vary, depending on the immunological status of 
the vaccinee 1. Accordingly, parenteral inactivated 
vaccines have been estimated to have an efficacy of only 
60-80% 2 . 
In recent years, considerable effort has been focused 
on the development of a live attenuated influenza virus 
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vaccine, as an alternative approach to prevent influenza. 
Vaccination by live virus involves exposure of susceptible 
individuals to infection with the attenuated virus, which 
stimulates secretory IgA and circulating IgG antibody 
responses, as well as other immune responses. One of the 
candidates, a temperature-sensitive (ts) reassortant 
vaccine, was evaluated but was associated with genetic 
instability in seronegative children 3'4. A series of 
cold-adapted (ca) reassortants between the ca master 
strains, A/Ann Arbor/6/60(H2N2) and B/Ann Arbor/ 
1/66, and recent wild-type isolates are now being 
intensively evaluated. The results indicate a strong ability 
to control influenza with the correct antigenicity, safety 
and efficacy. Several studies with live attenuated ca 
reassortant (CR) influenza A and B vaccines have shown 
these to be safe and antigenic in infants and young 
children 5-9. The present study evaluates the live 
attenuated tri-, bi-, and monovalent combinations of CR 
vaccines in institutionalized asthmatic children and 
severe psychomotor-retarded (S PR ) patients. This report 
details the relative absence of adverse reactions, 
significant serological responses and protective efficacy 
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of the vaccines against a nosocomial outbreak 
influenza A H1N1 observed in the winter of 1988 1989. 
of 
M A T E R I A L S  A N D  M E T H O D S  
Vaccine 
The CR vaccine strains employed in this study were 
CR-125(H1NI ), CR-149(H3N2) and CRB-117, which 
are genetic reassortants between ca master strains 
A/Ann Arbor/6/60(H2N2) and B/Ann Arbor/I/66, 
and their respective wild-type strains A/Kawasaki/9/86 
(H1NI), A/Los Angeles/2/87(H3N2), and B/Ann 
Arbor/I/86. Each vaccine virus contains the haemag- 
glutinin and neuraminidase genes of the wild-type strain 
and the remaining six internal genes from the parent ca 
donor strain. The vaccine preparations were provided by 
Chemo-Sero-Therapeutic Research Institute, Kumamoto, 
Japan; the titration of infectivity, safety testing in ferrets, 
and genotyping of vaccine preparations were performed 
at the University of Michigan. Experimental vaccines 
were prepared in specific pathogen-free (SPF) fertile 
chicken eggs inoculated by the allantoic route. The 
infected SPF allantoic fluid was concentrated and 
purified by centrifugation and ultrafiltration. Two CR 
vaccines, CR-125 and CR-149, were mixed and 
lyophilized as a bivalent form, while CRB-117 was 
lyophilized as a monovatent form. On administration of 
the trivalent CR vaccine containing both type A and B 
viruses (CR-AB), equal amounts of reconstituted 
influenza A bivalent (CR-A) and monovalent B(CR-B) 
vaccines were mixed. Reconstituted CR vaccines adjusted 
to contain 10 7 plaque-forming units (p.f.u.) per 0.3 ml 
of infectivity in Madin-Darby canine kidney (MDCK) 
cells for each virus were inoculated intranasally. 
Inactivated split vaccine, prepared by the Chemo-Sero- 
Therapeutic Research Institute to contain A/Yamagata/ 
120/86 (H 1N 1 ), A / Fukuoka/C29 / 85(H3N2 ), A / Sichuan/ 
2/87(H3N2) and B/Nagasaki/I/87, was administered 
subcutaneously (0.5 ml) twice with a 2-week interval. 
Volunteers 
Patients of the National Minami Fukuoka Chest 
Hospital were recruited to join the study, after informed 
consent was obtained from their parents. The hospital 
was divided into four wards: one ward (A, 50 beds) for 
asthmatic children, and three wards (B, C, and D, each 
with 40 beds) for the handicapped SPR children and 
young adults. A total of 142 volunteers - 39 in ward A, 
36 in ward B, 37 in ward C and 30 in ward D - were 
enrolled between November 1988 and March 1989. Eight 
groups were formed and were randomized to receive one 
of the combinations of CR vaccines or inactivated split 
vaccine. In ward A, 19 were inoculated with the trivalent 
CR-AB vaccine, and the remaining 20 were enrolled as 
controls with no vaccination. In ward B, 17 were 
inoculated with bivalent CR-A vaccine, 16 with 
monovalent CR-B vaccine, and the remaining three were 
not vaccinated. In ward C, 19 were inoculated with 
bivalent CR-A, 16 with inactivated vaccine, and the 
remaining two were not vaccinated. In ward D, all 30 
were immunized with inactivated vaccine (Table 1). 
Contraindications. included in the study were known 
allergy to egg protein or chicken feathers. 
Clinical observation 
Observations were made for any associated adverse 
reactions, daily for one week. In ward A, fever, upper 
respiratory tract symptoms, and bronchial asthma attack 
were recorded by physicians. In wards B, C, and D, fever 
and objective signs were carefully examined. Body 
temperature was measured twice daily, in the morning 
and afternoon, until the end of March 1989, to monitor 
the outbreak of influenza. 
Virus isolation 
Pharyngeal swabs from vaccinees who developed body 
temperature >37.5°C within 1 week of inoculation 
were collected into Eagle's Minimum Essential Medium. 
Virus isolation was performed in MDCK cell cultures. 
Pharyngeal swabs were also collected until March 1989 
from all the participants who developed influenza-like 
illness; virus isolation for these samples was done in 
MDCK cells and embryonated chicken eggs. 
Table 1 Study population, and clinical and virological responses of patients with bronchial asthma and with severe psychomotor retardation to 
cold-adapted reassortant (CR) influenza virus vaccines 
No. of 
Type of No. of Age (years) vaccinees No. of vaccinees 
War& Group vaccine vaccinees (mean ± s.d.) with fever ° with virus shedding e 
A 1 CR-AB ~ 19 11.1 ± 2.7 4 ~ 2(A H1N1), I (A  H3N2) 
2 None 20 10.0 ± 2.3 3" NT 
B 3 CR-A ~ 17 23.1 i 5.6 3 0 
4 CR-B b 16 21.4 _+ 7.1 3 I (B) 
5 None 3 16.7 4- 3.3 0 NT 
C 6 CR-A ~ 19 24.5 + 5.1 8 2(A H1N1), I (A H1N1 + A H3N2) 
7 Inactivated c 16 27.2 _+ 6.3 1 NT 
8 None 2 24.0 0 NT 
D 9 Inactivated C 30 13.3 ± 8.0 0 NT 
NR, not tested 
aPatients with bronchial asthma were in ward A, and those with severe psychomotor retardation were in wards, B, C and D 
°CR-AB: trivalent, CR-125(A H1N1), CR-149(A H3N2) and CRB-117(B); CR-A: bivalent (CR-125 and CR-149); CR-B: monovalent (CRB-117) 
/ / / / Clnactivated split vaccine containing A/Yamagata/120/86(HIN1 ), A/'Fukuoka/C29/85(H3N2), A/Sichuan/2/67(H3N2), and B/Nagasaki/1/87 
~Fever (>37.5°C) within 7 days after inoculation. One of four vaccinees and all three unvaccinated children with fever in ward A were serologically 
confirmed to be infected with adenovirus type 11 
ePharyngeal swabs were collected from vaccinees who developed fever after inoculation. All isolates possessed both cold-adapted and 
temperature-sensitive phenotypes 
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Serological testing 
Serum specimens were collected before vaccination, 4 
weeks after vaccination, and at the end of March 1989 
when the number of influenza infections abated. The 
standard haemagglutination-inhibition (HI) test was 
performed using the vaccine strains and the epidemic 
strain, A/Fukuoka/MF33M3/89 (H1N1), isolated from 
a hospital patient. 
Statistical analysis 
The geometric mean titres (GMTs) of HI antibodies 
before and after vaccination were statistically analysed 
by the paired t test. Student's t test was used to compare 
the GMTs between CR vaccine groups, inactivated 
vaccine groups, and non-vaccinated controls. For HI 
antibody titres of < 1:16, 1:8 was used for calculation 
of GMT, and 1:2048 was used for titres of >~ 1:2048. The 
significant HI antibody responses among vaccinees 
against three vaccine strains were analysed by McNemar's 
test, and the infection rates of the groups were compared 
by Fisher's exact test. 
RESU LTS 
Adverse reactions 
An outbreak of pharyngoconjunctival fever caused by 
adenovirus type 11 was confirmed in ward A on 25 
November 19881°, 3 days after inoculation of trivalent 
CR-AB vaccine; examination of adverse reactions 
associated with CR-AB vaccination was therefore 
difficult. During the epidemic with adenovirus, four 
vaccinees and three non-vaccinees became febrile in ward 
A, of which one and three were later confirmed infected 
with the virus. However, development or worsening of a 
bronchial asthma attack was not apparent among 
vaccinees. Of 36 vaccinees with bivalent CR-A in wards 
B and C, 11 cases (31%) developed body temperature 
higher than 37.5°C on the third and fourth days after 
inoculation, with the highest body temperature of 38.8°C 
and the average, 38.1°C. Of 16 vaccinees with monovalent 
CR-B, 3 ( 19% ) became febrile on the second to fifth days 
after inoculation (the highest body temperature was 
38.1 °C and the average 37.9°C). Febrile reactions among 
vaccinees improved within 1-2 days, and their general 
conditions were tolerable. In contrast, of 46 children 
immunized with inactivated split vaccine, only one 
developed elevated body temperature (37.8°C), on the 
first day after vaccination. Five non-vaccinees were not 
febrile during the examination period. 
Virus isolation 
Table 1 shows the degree of virus isolation from 
pharyngeal swabs of vaccinees who were febrile within 7 
days after inoculation. In group 1, inoculated with 
trivalent CR-AB vaccine, three strains of influenza A virus 
(two strains ofA H1N1 and one strain ofA H3N2) were 
recovered from three cases. Four strains of influenza A 
virus were isolated from three cases in group 6, inoculated 
with bivalent CR-A vaccine: H1N1 and H3N2 from one 
case and two isolates of H1N1 from two others. One 
type B isolate was recovered from a febrile child in group 
4, inoculated with monovalent CR-B vaccine. All isolates 
were confirmed to possess both ts and ca phenotypes. 
Serological responses after vaccination 
Table 2 summarizes the HI antibody titre response 
against each vaccine subtype. The GMTs of HI antibody 
against CR-125, CR-149 and CRB-117 were 1:300, 1:364 
and 1:281 before vaccination, and 1:816, 1:516 and 1:320 
after vaccination, respectively. Although no significant 
difference was observed between the GMTs of HI 
antibody against the three subtypes before vaccination, 
the GMT response to CR-125 following vaccination was 
greater than those to CR-149 and CRB-117. Sero- 
conversions or significant antibody rises of fourfold or 
greater were also observed: 27 (49.1%) of 55 vaccinees 
with CR-125, 12 (21.8%) of 55 with CR-149, and four 
(11.4%) of 35 with CRB-117. To analyse the influence 
of pre-existing HI antibody on vaccine response, the 
vaccinees were classified into three groups according to 
their HI antibody titres before vaccination. All 
seronegative vaccinees to each subtype showed sero- 
conversion. Significant HI antibody rises were also 
observed in subjects with HI titres of 1:16 to 1:64 before 
vaccination: 15 (88%) of 17 vaccinees for CR-125, five 
(36%) of 14 for CR-149, and three (27%) of 11 for 
Table 2 Hemagglutination-inhibition (HI) antibody responses among vaccinees with cold-adapted CR influenza virus vaccines 
GMT a of HI antibody 
Subtype of No. of Before After HI titre before No. responders~/ 
CR vaccine vaccinees vaccination ~ vaccination ~ vaccination no. vaccinees (%) 
CR-125(A HIN1 ) 55 299.8 
(groups 1, 3, and 6) 
CR-149(A H3N2) 55 364.1 
(groups 1, 3, and 6) 
CRB-117(B) 35 281.4 
(groups 1 and 4) 
815.7 <1:16 1/'1 ) 
p < ().001 1:16 ~ 1:64 15/17 ~ 27/55 (49.1) ~ 
>1:64 11/37 
515.8 <1:16 2/2 ") 
p < ().001 1:16 ~ 1:64 5/14 j~ 12/55 (21.8) ~ 
> 1:64 5/39 
320.0 <1:16 1/1 ") 
p <Y0.01 1:16 ~ 1:64 3//11 .~ 4/35 (11.4) 
>1:64 0/23 
aGMT, geometric mean titre 
~GMTs before vaccination against three subtypes were not significantly different 
GMT after vaccination against CR-125 was statistically higher than those against CR-149 and CRB-117 (p < 0.01 by Student's t test). The GMT against 
each subtype rose significantly after vaccination by the paired t test 
CSerological responders were defined as those showing fourfold or greater rises in HI titres 
~Responder rate for CR-125 was significantly higher than that for CR-149 (p < 0.01 by McNemar's test) 
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Table 3 Protective effect of cold-adapted reassortant (CR) influenza virus vaccines against the nosocomial outbreak of influenza A H1N1 
Type of No. of HI titre No. of patients No. of patients 
Ward Group vaccine vaccinees before outbreak with febrile illness with infection a (%) 
A 1 CR-AB 19 < 1:16 0 0 ) 0 ] 
1:16 ~ 1:64 2 0 ~ 0 0 ~ 0 (0) 
>1:64 17 0 0 
2 None 20 <1:16 3 0 ) 0 ) 
1:16 ~ 1:64 9 4 ~ 6 ~ 4 ~ 5 (25.0) c 
>1:64 8 2 1 
D 9 Inactivated 30 < 1:16 O 0 "~ 0 ] 
1:16 ~ 1:64 16 7 ~ 10 ~ 7 ~ 10 (33.3) ~ 
>1:64 14 3 3 
alnfection cases were defined as those showing fourfold or greater rises in HI antibody titres against A HIN1 virus (A/Fukuoka/MF33M3/89) isolated 
in the outbreak 
~One of six febrile patients in ward A, and one of ten in ward D were not serologically confirmed as having influenza A H1N1 infection 
CThe infection rate of unvaccinated controls (group 2) was statistically higher than that of CR-AB vaccinees (group 1 ) by Fisher's exact test (p < 0.05) 
~One of ten cases had a subclinical infection. The rate of children immunized with inactivated split vaccine (group 9) was statistically higher than that 
of CR-AB vaccinees (group 1) by Fisher's exact test (p < 0.01) 
CRB-117. In contrast, significant HI antibody titre rises 
were infrequent in those with titres >1:64  before 
vaccination: 11 (30%) of 37 vaccinees for CR-125, five 
(13%) of 39 for CR-149, and none of 20 for CRB-117. 
No significant HI antibody titre rise to each vaccine strain 
was observed in the 25 non-vaccinees. 
Among the 46 vaccinees with inactivated split vaccine, 
the GMTs of HI antibody to the vaccine strains, A/ 
Yamagata/120/86(H1N1 ), A/Fukuoka/C29/85(H3N2) ,  
A/Sichuan/2/87(H3N2) ,  and B/Nagasak i / i /87  were 
1:197, 1:276, 1:73, and 1:145, respectively, before 
vaccination. After immunization, the GMTs rose to 
1:661, 1:773, 1:551, and 1:467; significant HI antibody 
titre rises were observed in 27 cases (59%), 26 (57%), 
31 (67%), and 25 (54%), respectively (data not shown ). 
Protective effect against outbreak of influenza A HIN1 
A nosocomial outbreak of influenza-like illness was 
observed in wards A and D in the winter of 1988 1989, 
with influenza H1N1 strains isolated from the children. 
As shown in Table  3, all the infected children were 
clustered in only two groups, non-vaccinees and 
recipients of inactivated vaccine. During the period from 
29 December, 1988 to 14 January 1989, five cases were 
serologically confirmed as influenza H1N1 in ward A; 
ten other cases were confirmed in ward D in the period 
8 16 January. Fourteen of these 15 cases were febrile, 
with body temperatures of 38.2-41.0°C persisting for 
2 10 days, and developed various upper respiratory tract 
symptoms. Of 19 vaccinees given trivalent CR-AB in 
ward A, none showed clinical illness or serological 
response to H1N1, but five (25%) of 20 non-vaccinees 
became infected. Of 30 patients given inactivated vaccine, 
ten (33 % ), including one with subclinical infection, were 
shown by serology to be infected with H1N1. No 
influenza activity was observed in wards B and C, and 
there was no significant HI antibody rise to the current 
H 1N 1 subtypes. 
D I S C U S S I O N  
This report has documented that, first, no severe adverse 
reactions are observed after vaccination with CR vaccines 
(bivalent A, monovalent B, and trivalent A and B) to 
high-risk seropositive and seronegative institutionalized 
patients with bronchial asthma and SPR. Secondly, none 
of the CR vaccinees became infected during an outbreak 
of influenza A H1N1. 
Immunization against influenza has been recommended 
in high-risk patients, especially those with chronic 
pulmonary diseases, including bronchial asthma 11-14 
Prevention against nosocomial influenza is also very 
important among institutionalized SPR patients. However, 
the efficacy of the presently available inactivated 
influenza split vaccine is marginal. CR vaccines are now 
being intensively evaluated as a more effective influenza 
vaccine, and their efficacy in healthy adults and children 
has been well reported 1 s.16. The possible risk of adverse 
effects to patients with chronic pulmonary diseases 
following administration of the CR vaccine has been a 
concern, but Atmer et al. 17 reported that the CR vaccine 
did not have any untoward effects on pulmonary function 
after nasal administration to adults with bronchial 
asthma. In the present trial of trivalent CR vaccine to 
high-risk children, no bronchial asthma attacks associated 
with vaccination were observed; however, the unforeseen 
nosocomial outbreak of adenovirus type 11 l° did not 
permit a definitive evaluation of the side effects related 
to CR vaccination. Among SPR patients, body 
temperatures > 37.5°C were observed in 31% of CR-A 
vaccinees and 19% of CR-B vaccinees, but the duration 
was limited to 1 2 days and their general conditions 
were tolerable. In Japan, it is very difficult to evaluate 
the CR vaccine in seronegative volunteers because most 
children are seropositive through the fiat of annual 
immunizations with inactivated vaccine. Although the 
number of seronegative children was small in our study, 
no severe side effects associated with the CR vaccines 
were observed among them. Therefore, the CR vaccine 
is well attenuated for SPR patients as well as asthmatic 
children. 
The CR vaccines, both types A and B, have been 
proven to be genetically stable, and do not show any 
transmission in spite of virus shedding after vaccin- 
ation s,9'18'19. In this study, influenza viruses (A H1NI 
and H3N2, and B ) were recovered following inoculation, 
but all the isolates possessed both ts and ca phenotypes. 
Also, no secondary transmission to non-vaccinees within 
the same wards was documented, and this was 
serologically confirmed. 
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Influenza outbreaks with different type A and B viruses 
have been frequently encountered recently, and multi- 
valent inactivated vaccines have therefore been routinely 
recommended. For CR vaccine development, interference 
of viral replication when different subtypes are used in 
combination may become a problem; however, to date, 
immunological responses comparable to monovalent 
vaccine have been reported for bivalent type A vaccine 
(H1N1, H3N2) TM and trivalent vaccine (H1N1, H3N2, 
and B) in children 2°. In this study, significant increases 
in HI antibody titres to each subtype were lower (CR-125 
49.1% ,CR-149 21-8% , and CRB-11711.4% )thanthose 
reported so far. It is likely that these results are mainly 
due to pre-existing antibody levels among vaccinees, 
rather than interference between viruses. Indeed, all 
seronegative vaccinees showed seroconversion, and no 
significant differences in HI antibody response to each 
vaccine strain were confirmed when comparison was 
made between trivalent CR-AB (group 1 ), bivalent CR-A 
(groups 3 and 6), or monovalent CR-B (group 4) 
vaccinees. Thus, the development of multivalent CR 
vaccines may be practical, resulting in a vaccine that is 
potentially more effective against outbreaks of influenza. 
Thus far, studies on antigenicity and efficacy of CR 
vaccines have been performed mainly on seronegative 
adults and children. However, seropositive subjects also 
frequently become infected with influenza, and the CR 
vaccine, in practice, wil be used blindly, independent of 
pre-existing antibody status. Therefore, antigenicity and 
efficacy in seropositive subjects are important determin- 
ants and need to be investigated. Clements e t  al .  5 reported 
good serological response to CR-A vaccine in seropositive 
adults. In children, reports on vaccination with 
monovalent CR-B vaccine 9 and trivalent CR-AB (H 1N 1, 
H3N2, and B) vaccine 2° showed moderate rises in 
antibody titres. In the present study, vaccinees who 
possessed relatively low HI antibody titres ( ! : 16 to 1:64) 
to H1N1, H3N2 and B before vaccination responded 
better than those with higher HI antibody titres ( > 1:64). 
The CR vaccine response greatly depends on pre-existing 
antibody titres before vaccination; protective immunity 
is mainly achieved in susceptible persons. 
The protective effects of CR-A H3N2 vaccine 15.19 and 
CR-A H1N1 vaccine 21 against natural influenza 
outbreaks have been documented. Our present report is 
the first indication of the protection offered by the 
trivalent CR vaccine against a nosocomial outbreak of 
influenza (H1N1) in institutionalized patients. The 
outbreak of influenza was observed in ward A for 
asthmatic children and ward D for SPR patients. In ward 
A, 25% of 20 non-vaccinees were serologically shown to 
have had influenza, whereas no infection was confirmed 
among the vaccinees with trivalent CR-AB. In ward D, 
all SPR patients were immunized with inactivated split 
vaccine, and were shown to have relatively high HI 
antibody titres, with GMT of 1:661 to H1N1, but 33% 
of 30 vaccinees became infected with H1N1. Antigenic 
differences between the epidemic HIN1 strain (A/ 
Fukuoka/MF33M3/89), CR-125 (A/Kawasaki/9/86), 
and the inactivated vaccine strain (A/Yamagata/120/86) 
were negligible. It should be noted that the CR trivalent 
vaccine prevented influenza in ward A, but the inactivated 
vaccine did not in ward D. It might be difficult to make 
a final conclusion at this time as to the relative efficacy 
of the two vaccine types, because comparative studies 
were not performed in the same wards. However, the 
inactivated split vaccine clearly did not provide protective 
immunity in this study. 
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